IRC-083927

Overview

IRC-083927 is an orally effective tubulin inhibitor. IRC-083927 binds to the colchicine site on tubulin to inhibit its polymerization, thereby inducing G2-M phase cell cycle arrest in tumor cells. IRC-083927 significantly inhibits endothelial cell proliferation and in vitro angiogenesis, and exhibits remarkable antitumor activity. IRC-083927 can be widely applied in relevant studies on human cervical cancer , breast cancer , pancreatic cancer , prostate cancer , as well as small cell and non-small cell lung cancer .

Application

Products | Products > Disease Areas > Respiratory Cancer | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Non-Small Cell Lung Cancer | Products > Disease Areas > Cancer | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Lung Cancer | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Cytoskeleton | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Microtubule/Tubulin

Product Information

• Catalog No.: HY-111015A
• CAS No.: 955157-23-0
• Molecular Formula: C22H19FN4O4S
• Molecular Weight: 454.47
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source